Flax Pond Capital LLC Invests $2.20 Million in Organogenesis $ORGO

Flax Pond Capital LLC acquired a new stake in Organogenesis (NASDAQ:ORGO) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 424,191 shares of the company’s stock, valued at approximately $2,197,000. Flax Pond Capital LLC owned approximately 0.33% of Organogenesis at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in ORGO. Caitong International Asset Management Co. Ltd bought a new stake in Organogenesis during the fourth quarter worth approximately $75,000. Invesco Ltd. boosted its stake in Organogenesis by 9.9% during the 4th quarter. Invesco Ltd. now owns 175,219 shares of the company’s stock valued at $908,000 after purchasing an additional 15,790 shares in the last quarter. Mercer Global Advisors Inc. ADV bought a new position in Organogenesis during the 4th quarter valued at $57,000. XTX Topco Ltd acquired a new position in shares of Organogenesis during the 4th quarter valued at $79,000. Finally, Oxford Asset Management LLP acquired a new position in shares of Organogenesis during the 4th quarter valued at $66,000. Institutional investors and hedge funds own 49.57% of the company’s stock.

Organogenesis Price Performance

Shares of NASDAQ:ORGO opened at $2.44 on Friday. The company has a market capitalization of $313.98 million, a PE ratio of -12.84 and a beta of 1.32. The company has a debt-to-equity ratio of 0.05, a quick ratio of 3.16 and a current ratio of 3.53. The stock has a fifty day moving average of $2.46 and a 200-day moving average of $3.36. Organogenesis has a one year low of $2.04 and a one year high of $7.08.

Organogenesis (NASDAQ:ORGO) last issued its earnings results on Thursday, May 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.08). The company had revenue of $37.23 million during the quarter, compared to analyst estimates of $43.26 million. Organogenesis had a positive return on equity of 9.63% and a negative net margin of 0.84%.

Analyst Upgrades and Downgrades

ORGO has been the topic of a number of research reports. Weiss Ratings downgraded Organogenesis from a “hold (c)” rating to a “sell (d)” rating in a research note on Monday, May 11th. Truist Financial started coverage on Organogenesis in a report on Thursday, May 28th. They set a “hold” rating and a $3.00 target price on the stock. UBS Group set a $3.00 price target on shares of Organogenesis in a research report on Thursday, May 28th. Wall Street Zen raised shares of Organogenesis from a “strong sell” rating to a “sell” rating in a report on Saturday. Finally, BTIG Research downgraded shares of Organogenesis from a “buy” rating to a “neutral” rating in a report on Friday, May 8th. One equities research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $5.75.

About Organogenesis

Organogenesis Inc operates as a regenerative medicine company focused on the development, manufacturing and commercialization of therapeutic solutions for wound care, surgical repair and sports medicine. The company’s product portfolio addresses a range of acute and chronic tissue repair needs, leveraging bioengineered skin substitutes, human placental-derived products and other allografts designed to promote healing and reduce scarring. Organogenesis markets its therapies to hospitals, outpatient clinics, wound care centers and other healthcare providers.

Key offerings include Apligraf, a living skin substitute for treatment of diabetic foot ulcers and venous leg ulcers; Dermagraft, a cryopreserved human fibroblast-derived dermal substitute; Grafix, a placental membrane allograft for complex and chronic wounds; and TheraSkin, a cryopreserved human skin allograft used in surgical and reconstructive procedures.